Discoveries from stem cell research could lead not only to breakthrough treatments for scores of conditions like diabetes, Parkinson's, heart disease, and multiple sclerosis, but they also holds the potential for unlocking how diseases manifest and could bring new preventive therapies to the masses.
Just days ago, the FDA approved the first human trial of an embryonic stem-cell therapy for 10 patients paralyzed by spinal cord injuries. This is exciting news for many who suffer with lifelong diseases or injuries. These poor souls are frustrated by the seemingly glacial pace of research and the political and religious debates that have limited federal funding.
Indeed, as Time magazine points out this week, many of today's leading stem cell scientists are conducting research abroad in Britain, Singapore, China, and other destinations where the government is more supportive and receptive. Thanks to modern technology these clinical researchers have networked across the globe to advance their discoveries well beyond the hype.
As legitimate and ethical research has emerged abroad, private stem cell clinics have also set up shop in countries friendly to their business. Numerous clinics around the world are aggressively marketing unproven and perhaps risky stem cell interventions directly to patients, according to the International Society for Stem Cell Research.
No one has figured out how many patients have sought stem cell therapy abroad, but experts suspect they number in the thousands. Far too many of these desperate people are paying thousands of dollars on stem cell injections based on empty promises and patient testimonials.
ISSCR says the new guidelines were created by a multidisciplinary task force of stem cell researchers, clinicians, ethicists, and regulatory officials from 13 countries. The group warns: "The marketing of unproven stem cell interventions is especially worrisome in cases where patients with severe diseases or injuries travel across borders to seek treatments purported to be stem cell-based 'therapies' or 'cures' that fall outside the realm of standard medical practice. Patients seeking medical services abroad may be especially vulnerable because of insufficient local regulation and oversight of host clinics."
Private clinics that market stem cell tourism without real evidence these therapies work threaten more than just the patients they treat; they run the risk of casting the medical travel industry as a whole in the role of the snake oil salesman. Often in this space I discuss the rising demand for medical travel options, but ethical considerations of medical travel will continue to be debated for a long time to come.
Bottom line, the spirit of caveat emptor has no place in medical travel or the healthcare industry as a whole.
View Rick Johnson's profileNote: You can sign up to receiveHealthLeaders Media Global, a free weekly e-newsletter that provides strategic information on the business of healthcare management from around the globe.
Tom Daschle withdrew his name on Tuesday as President Obama's nominee to lead the Health and Human Services Department, afer tax issues had developed into a troublesome distraction for President Obama. The president said he accepted Daschle's sudden withdrawal "with sadness and regret."
California's labor battle over who will represent tens of thousands of hospital workers will be determined in voting booths around the state. The National Union of Healthcare Workers, formed last week by the ousted leaders of United Healthcare Workers West, has asked state officials to conduct elections at 64 healthcare facilities where it says a majority of employees currently represented by Oakland-based UHW want to join the new group.
After months of quiet planning for a new academic medical complex in New Orleans, the temperature is rising between Louisiana State University System officials and opponents of the school's proposed site. LSU leaders say they are reacting to what they say is misinformation and cheap shots by preservationists and other opponents of the proposed complex. Walter Gallas, the New Orleans field director for the National Trust for Historic Preservation, said LSU officials have earned the criticism, and he said the university is to blame for any rhetorical escalation.
Harvard Medical School plans to strengthen its conflict-of-interest rules for doctors and researchers. The move comes amid a U.S. Senate investigation into several faculty members and a new state law that will make public some of the payments doctors receive from pharmaceutical and medical-device companies. Many top medical schools have adopted stricter policies in the past two years. Last year, the American Medical Student Association graded Harvard with an F on its conflict-of-interest policy because it does not address issues like whether companies can provide gifts and meals for faculty.
A consumer group seeking Medicare billing records to help grade doctors on quality said it's not giving up despite a reversal from a federal appeals court. The case is being closely watched as an important battle in the effort to reshape the nation's healthcare system. Consumer advocates, employers, and insurers argue that access to Medicare claims filed by doctors' offices could help independent groups monitor quality and ferret out waste. But doctors are worried that such disclosures would violate their privacy, and that ratings could portray some physician's offices inaccurately.